Akebia Therapeutics Inc. (AKBA)
NASDAQ: AKBAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AKBA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $107.04M
- EPS (TTM)
- -$0.17
- Dividend yield
- None
- 52-week range
- 0.361 – 1.73
- Day range
- 0.3849 – 0.4331
- Volume / Avg
- 4.57M / 8.05M
- Beta
- —
- Shares outstanding
- 277.66M
52-week range
AKBA stock today
Shares of Akebia Therapeutics (AKBA) finished lower on Nov 20 at $0.3855, a drop of 8.71% or $0.0368 per share, versus the S&P 500's 3.70% decline. Shares are 77.7% below their 52-week high of $1.73, set on Dec 22, 2025 and 6.8% above the 52-week low of $0.361, near the bottom of the past year's range. AKBA is down 76.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 75.1%.
Akebia Therapeutics has posted a net loss over the last twelve months (EPS of -$0.17), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Akebia Therapeutics
Company profileAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. John P. Butler MBA
- Headquarters
- Waltham, MA
- Employees
- 194
- IPO year
- 2014
- Website
- akebia.com
Financial highlights
Full financialsIn fiscal 2025, Akebia Therapeutics generated $236.2 million in revenue, up 47.5% from fiscal 2024. Akebia Therapeutics reported a net loss of $5.3 million, compared with a loss of $69.4 million a year earlier. Gross margin was 83.3% (up from 60.6%) and operating margin 9.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $236.20M | $160.18M | $194.62M | $292.48M | $211.65M |
| Growth | +47.46% | -17.70% | -33.46% | +38.19% | -28.17% |
| Net income | $-5.34M | $-69.41M | $-51.92M | $-94.23M | $-282.02M |
| EPS (diluted) | $-0.02 | $-0.33 | $-0.28 | $-0.52 | $-1.70 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$3.00+678.21%
- Strong buy 1
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.05 vs $-0.03
- Surprise
- -66.67%
AKBA news
All AKBA news- Akebia Therapeutic’s Vafseo® (vadadustat) Granted Additional PatentGlobeNewswire
- Akebia Therapeutics, Inc. Enters into $140.0 million Senior Secured Term Loan FacilityNasdaq
- Akebia Enters into Term Loan Facility with Symbiotic Capital Worth Up to $140 MillionGlobeNewswire
- Akebia (AKBA) Q3 2026 Earnings Call TranscriptNasdaq
- Akebia Therapeutics Reports Third Quarter 2026 Financial ResultsNasdaq
- Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business HighlightsGlobeNewswire
- U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney WeekGlobeNewswire
- Akebia Therapeutics, Inc. Receives Nasdaq Minimum Bid Price Deficiency NoticeNasdaq
Akebia Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BGMBGM Group Ltd. Class A | 8.13 | 0.00% | $108.57M | vs AKBA |
| SPRBSpruce Biosciences Inc. | 38.00 | -6.15% | $109.21M | vs AKBA |
| MENSJyong Biotech Ltd. | 1.45 | -17.14% | $110.24M | vs AKBA |
| GNLXGenelux Corporation | 2.17 | -4.82% | $103.36M | vs AKBA |
| FHTXFoghorn Therapeutics Inc. | 1.72 | -3.37% | $103.14M | vs AKBA |
| IMUXImmunic Inc. | 6.99 | -5.41% | $111.01M | vs AKBA |
| OKUROnKure Therapeutics Inc. Class A | 2.70 | -2.17% | $111.21M | vs AKBA |
| ORGOOrganogenesis Holdings Inc. Class A | 0.7716 | -2.23% | $100.16M | vs AKBA |
Indexes, lists and sector
Akebia Therapeutics stock FAQ
What is Akebia Therapeutics's stock price today?
AKBA last traded at $0.3855 as of Nov 20, 4:00 PM EST, down 8.71% on the day. Prices are delayed at least 15 minutes.
Who is Akebia Therapeutics's CEO?
Mr. John P. Butler MBA is the chief executive officer of Akebia Therapeutics Inc., which has about 194 employees.
What is the AKBA 52-week high?
The 52-week high for AKBA is $1.73 and the 52-week low is $0.361. The stock is currently 77.7% below its high.